ZX-55109-96 | SARS-CoV-2 (COVID-19) IgG ELISA Kit
A novel coronavirus, named SARS-CoV-2 or 2019-nCoV, has caused an ongoing global pandemic, called COVID-19 in 2020. The pneumonia-like COVID-19 outbreak started in Wuhan City, the capital of Hubei province, in China, and quickly spread around the world within just few months. The SARS-CoV-2 is a human coronavirus that is genetically different from the other common human coronaviruses such as 229E, NL63, OC43, HKU1, which cause seasonal acute respiratory illnesses. It is also genetically distinct from the two newer human coronaviruses, MERS-CoV and SARS-CoV.
The SARS-CoV-2 virus is a positive-sense single stranded RNA virus, and has four structural proteins, known as the S (spike), E (envelope), M (membrane), and N (nucleocapsid) proteins. The N protein holds the RNA genome, while the S, E, and M proteinstogether create the viral envelope. The S protein mediates viral entry into host cells by initial binding to the host ACE2 receptor through the receptor-binding domain (RBD) in the S1 subunit and then fusing the viral and host membranes through the S2 subunit. The RBD residues 331 to 524 of the S1 protein elicits the production of antibodies in the host.
The primary and golden standard method to diagnose SARS-CoV-2 infection is a PCR-based assay which detects the RNA of the virus derived from throat and nasal swabs. For analyzing SARS-CoV-2 using qPCR methods use either our SARS-CoV-2–RT-qPCR Detection kit (N&RP) Cat. No. ZX-22102-100 or Coronavirus (2019-nCoV) Real Time-qPCR Detection Kit Cat. No. ZX-22100-100.
Serological assays on the other hand, allow the study of the immune response to SARS-CoV-2 in a qualitative and quantitative manner. Serological assays determine the precise rate of infection in an affected area, which is an essential variable to accurately define the infection fatality rate. Serological assays will allow for the identification of individuals who mounted strong antibody responses and who could serve as donors for the generation of serum antibody-based therapeutics. They will also permit health authorities to determine who may be immune and who is not. This information may be very useful for deploying healthcare workersin a strategic mannerto limit the risk of exposure and inadvertentspread of the virus. It could also allow proportions of the population that have already acquired immunity to go back to ‘normal life’.
Technical Support: Customer satisfaction is very important to us. Please call us at +49(0)30 81309085 or send an email to technical[at]zellx.de with your technical questions. A member of our scientific staff will be glad to assist you.